

informed consent. *Frequency of*

*Response:* One-time data collection.

*Affected Public:* Individuals.

Type of respondents	Estimated number of respondents	Estimated number of responses per respondent	Average burden hours per responses	Estimated total annual burden hours requested
Blood Donors .....	78,000	1	.3333	25,997

The annualized cost to respondents is estimated at: \$259,974 (based on \$10 per hour). There are no Capital Costs to report. There are no Operating or Maintenance Costs to report.

#### Request For Comments

Written comments and/or suggestions from the public and affected agencies are invited on one or more of the following points: (1) Whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) The accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Ways to enhance the quality, utility, and clarity of the information to be collected; and (4) Ways to minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical or other technological collection techniques or other forms of information technology.

#### Direct Comments To OMB

Written comments and/or suggestions regarding the item(s) contained in this notice, especially regarding the estimated public burden and associated response time, should be directed to the: Office of Management and Budget, Office of Regulatory Affairs, New Executive Office Building, Room 10235, Washington, DC 20503, Attention: Desk Officer for NIH. To request more information on the proposed project or obtain a copy of the data collection plans and instruments contact: Dr. George J. Nemo, Group Leader, Transfusion Medicine, Scientific Research Group, Division of Blood Diseases and Resources, NHLBI, NIH, Two Rockledge Centre, Suite 10042, 6701 Rockledge Drive, MSC 7950, Bethesda, MD 20892-7950, or call non-toll free number (301) 435-0075 or e-mail your request, including your address to: nemog@gwgate.nhlbi.nih.gov.

#### Comments Due Date

Comments regarding this information collection are best assured of having their full effect if received on or before January 28, 1998.

Dated: December 17, 1997.

**Sheila E. Merritt,**

*Executive Officer, NHLBI.*

[FR Doc. 97-33745 Filed 12-24-97; 8:45 am]

BILLING CODE 4140-01-M

#### DEPARTMENT OF HEALTH AND HUMAN SERVICES

##### National Institutes of Health

##### Cooperative Research and Development Agreement (CRADA) Opportunity and/or Licensing Opportunity for Materials and Methods for Protection of Tissue From Ischemic Damage

**AGENCY:** National Institutes of Health, Public Health Service, DHHS.

**ACTION:** Notice.

**SUMMARY:** The National Institutes of Health is seeking CRADA partners and/or licensees for the further development, evaluation, and commercialization of materials and methods for protecting tissues from cell injury by Ischemia. The invention claimed in U.S. Patent Application Serial No. 60/053,843, "12(S)=HpETE (A 12=Lipoxygenase Metabolite) Significantly Reduces Cell Injury," is available for licensing (in accordance with 35 U.S.C. 207 and 37 CFR Part 404) and/or further development under one or more CRADAs in several clinically important applications as described below in the **SUPPLEMENTARY INFORMATION.**

**DATES:** CRADA proposals should be received on or before March 30, 1998 for priority consideration. However, CRADA proposals submitted thereafter will be considered until a suitable CRADA Collaborator is selected.

**ADDRESSES:** CRADA proposals and questions should be addressed to Dr. Jonathan Gottlieb, National Heart, Lung, and Blood Institute, Technology Transfer Service Center, 31 Center Drive MSC 2490, Room 1B32, Bethesda,

Maryland 20892-2490; Telephone: 301/402-5579; Fax: 301/594-3080; E-mail: GottlieJ@gwgate.nhlbi.nih.gov.

Questions about the licensing opportunity should be addressed to Carol Lavrich, Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; Telephone 301/496-7735 ext. 287; Fax 301/402-0220; E-mail: Carol—Lavrich@nih.gov.

**SUPPLEMENTARY INFORMATION:** Ischemia and reperfusion injury are significant causes of tissue damage in diseases and conditions such as heart attack, stroke and in organ transplantation. Recently, scientists at the National Institute of Environmental Health Sciences and Duke University, while investigating the phenomena of preconditioning, discovered and developed a highly effective method for protecting tissues from cell injury by ischemia by use of 12(S)=HpETE.

Previously developed treatments to prevent ischemic damage are greatly limited in their effectiveness. TPA, routinely used to dissolve blood clots, thereby allowing greater blood flow, does not prevent ischemic tissue injury. Aspirin has been shown to have only a small protective effect in the cardiovascular system. However, the above new method demonstrates a dramatic protective effect—up to 82% recovery in initial studies—when administered during injury, as seen in animal models. The protective effect of 12(S)-HpETE was discovered during investigation of the 12-lipoxygenase-related protective effect of ischemic preconditioning and, unlike other agents, 12(S)-HpETE has no known undesirable side effects.

Uses of such an invention may include treatment of tissue during angioplasty and treatment of organs intended for transplantation to limit the chance of damage.

This research was published in *Circulation Research* 76: 457-467, 1995.

Information about the patent application and pertinent information not yet publicly described can be obtained under a Confidential

Disclosure Agreement. Respondees interested in licensing the invention(s) will be required to submit an Application for License to Public Health Service Inventions. Respondees interested in submitting a CRADA proposal should be aware that it may be necessary to secure a license to the above patent rights in order to commercialize products arising from a CRADA.

Dated: December 16, 1997.

**Barbara M. McGarey,**

*Deputy Director, Office of Technology Transfer.*

[FR Doc. 97-33746 Filed 12-24-97; 8:45 am]

BILLING CODE 4140-01-M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Neurological Disorders and Stroke; Notice of Meetings

Pursuant to Pub. L. 92-463, notice is hereby given of meetings of the National Institute of Neurological Disorders and Stroke (NINDS).

The National Advisory Neurological Disorders and Stroke Council and its subcommittee meetings will be open to the public as indicated below. Attendance by the public will be limited to space available.

The meetings will be closed to the public as indicated below in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. and sec. 10(d) of Pub. L. 92-463, for the review, discussion and evaluation of individual grant applications.

These applications and discussions could reveal confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Summaries of meetings, rosters of committee members, and other information pertaining to the meetings can be obtained from the Executive Secretary or the Scientific Review Administrator indicated. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact the Executive Secretary listed for the meeting.

*Name of Committee:* The Planning Subcommittee of the National Advisory Neurological Disorders and Stroke Council.

*Date:* February 11, 1998.

*Place:* National Institutes of Health, Building 31, Conference Room 8A28, 9000 Rockville Pike, Bethesda, MD 20892.

*Closed:* 1:30 p.m.—recess.

*Name of Committee:* National Advisory Neurological Disorders and Stroke Council.

*Date:* February 12-13, 1998.

*Place:* National Institutes of Health, Building 31, Conference Room 6, 9000 Rockville Pike, Bethesda, MD 20892.

*Open:* February 12, 8:30 a.m.—approximately 3:00 p.m.

*Agenda:* A report by the Acting Director, NINDS; a report by the Director, Division of Extramural Activities, NINDS; a report by the Scientific Director, NINDS; and a scientific presentation by a NINDS intramural scientist.

*Closed:* February 13, approximately 3:00 p.m.—recess; February 14, 8:30 a.m.—adjournment.

*Executive Secretary:* Constance W. Atwell, Ph.D., Director, Division of Extramural Activities, NINDS, National Institutes of Health, Bethesda, MD 20892, Telephone: (301) 496-9248.

The following meetings will be totally closed to review and evaluate grant applications:

*Name of Committee:* National Institute of Neurological Disorders and Stroke Initial Review Group (Neurological Sciences and Disorders A).

*Date:* February 8-9, 1998.

*Time:* February 8, 8:30 a.m. to recess; February 9, 8:30 a.m. to adjournment.

*Place:* The Enclave Suites, 6165 Carrier Drive, Orlando, FL 32819.

*Contact Person:* Dr. Katherine Woodbury, Scientific Review Administrator, Scientific Review Branch, NINDS, National Institutes of

Health, Federal Building, Room 9C-10, Bethesda, MD 20892, (301) 496-9223.

*Name of Committee:* National Institute of Neurological Disorders and Stroke Initial Review Group (Neurological Sciences and Disorders B).

*Date:* February 18-20, 1998.

*Time:* February 18, 7:00 p.m.—recess; February 19, 8:00 a.m.—recess; February 20, 8:00 a.m. to adjournment.

*Place:* Crowne Plaza Hotel, 14th and K Streets, Washington, DC 20005.

*Contact Person:* Dr. Paul Sheehy, Scientific Review Administrator, Scientific Review Branch, NINDS, National Institutes of Health, Federal Building, Room 9C-10, Bethesda, MD 20892, (301) 496-9223.

*Name of Committee:* National Institute of Neurological Disorders and Stroke Training Grant and Career Development Review Committee.

*Date:* February 20, 1998.

*Time:* 8:00 a.m. to adjournment.

*Place:* Wyndham Bristol Hotel, 2430 Pennsylvania Avenue, NW., Washington, DC 20037.

*Contact Person:* Dr. Alfred Gordon, Scientific Review Administrator, Scientific Review Branch, NINDS, National Institutes of Health, Federal Building, Room 9C-10, Bethesda, MD 20892, (301) 496-9223.

(Catalog of Federal Domestic Assistance Program No. 93.853, Clinical Research Related to Neurological Disorders; No. 93.854, Biological Basis Research in the Neurosciences).

Dated: December 18, 1997.

**LaVerne Stringfield,**

*NIH Committee Management Officer.*

[FR Doc. 97-33747 Filed 12-24-97; 8:45 am]

BILLING CODE 4140-01-M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Division of Research Grants; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings that are being held to review grant applications:

Study section/contact person	February-March 1998 meetings	Time	Location
<b>AIDS and Related Research Initial Review Group</b>			
AIDS & Related Research 1, Dr. Sami Mayyasi, 301-435-1216.	Mar. 4-5 .....	8:00 a.m. ....	Hilton Hotel, Palm Springs, CA.
AIDS & Related Research 2, Dr. Gilbert Meier, 301-435-1219.	Mar. 13 .....	8:00 a.m. ....	Holiday Inn, Chevy Chase, MD.
AIDS & Related Research 3, Dr. Bruce Maurer, 301-435-1225.	Mar. 4-5 .....	8:30 a.m. ....	Hilton Hotel, Palm Springs, CA.
AIDS & Related Research 4, Dr. Mohindar Poonian, 301-435-1218.	Mar. 12-13 .....	8:30 a.m. ....	Olympia Hotel, Park City, UT.
AIDS & Related Research 5, Dr. Mohindar Poonian, 301-435-1218.	Mar. 3 .....	8:30 a.m. ....	Hyatt Regency Hotel, Bethesda, MD.